GNG2抗体—艾普蒂

+ +

•  

   

     Gel: 10%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Human fetal brain tissue, mouse brain tissue, Primary antibody: P08382(GNG2 Antibody) at dilution 1/350, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 2 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gasrtic cancer tissue using P08382(GNG2 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain  tissue using P08382(GNG2 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

The GNG2 antibody is a research tool designed to detect and study the G protein subunit gamma 2 (GNG2), a component of heterotrimeric G proteins involved in intracellular signaling. G proteins, composed of α, β, and γ subunits, relay signals from G protein-coupled receptors (GPCRs) to downstream effectors, regulating processes like neurotransmission, hormone secretion, and cell growth. GNG2 specifically belongs to the gamma subunit family, which contributes to the diversity of G protein complexes by pairing with different β subunits. This pairing influences membrane localization, receptor interaction, and effector activation.

GNG2 is expressed in various tissues, including the brain, heart, and immune cells, and has been implicated in neurological functions, cardiovascular regulation, and immune responses. Dysregulation of GNG2 is associated with diseases such as cancer, neurodevelopmental disorders, and cardiovascular pathologies. For example, altered GNG2 expression has been observed in gliomas and breast cancer, suggesting a role in tumor progression.

Antibodies against GNG2 enable researchers to investigate its expression, localization, and interactions via techniques like Western blotting, immunohistochemistry, and co-immunoprecipitation. These studies help unravel GNG2's functional roles in health and disease, aiding the development of targeted therapies. Validation of GNG2 antibodies typically includes testing specificity using knockout controls or siRNA-mediated knockdown to ensure accurate detection. As GPCR signaling remains a major therapeutic target, understanding GNG2's contributions through antibody-based research holds significant biomedical relevance.